ensifentrine vs KIT2014

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Obstructive Pulmonary Disease

Shared mechanism: PDE3/PDE4 · full Chronic Obstructive Pulmonary Disease pipeline

ensifentrine · Ohtuvayre

Marketed by Merck & Co. and partners

Approved in Chronic Obstructive Pulmonary Diseasesmall molecule
Reliable signal

NCT04542057 · Phase 3 · completed

This was a large (790-patient), randomized, quadruple-blinded, placebo-controlled Phase 3 trial with a hard clinical/lung-function primary endpoint (change in FEV1 area under the curve over 12 hours), and the ensifentrine group showed a statistically significant improvement over placebo on that primary comparison. The randomization, blinding, active placebo control, adequate sample size, and clear statistically significant result in the favorable direction together support a strong grade.

Next expected readout: March 2027 · NCT05270525 (registry estimate)

Reported efficacy

Average forced expiratory volume in 1 second (FEV1) area under the curve (AUC)0-12h (12 weeks): Placebo-corrected change from baseline in FEV1 AUC0-12h at Week 12: +110 mL for ensifentrine (p<0.0001) (met)

Result source: NCT05743075

KIT2014

Developed by Kither Biotech

Phase 1/2 in Chronic Obstructive Pulmonary Diseasepeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: March 2027 · NCT07668518 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Chronic Obstructive Pulmonary Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointensifentrineKIT2014
Moderate or severe exacerbations, annualised rate—Not posted · NCT05743075—Not reported
Trough FEV1, change-0.0 vs -0.0±0 vs placebowk 24 · n 498NCT04542057
14 other results
  • -0.0 vs -0.0 wk 24 · n 477 · Phase 3 · secondary NCT04535986
  • 0.0 vs -0.0 wk 12 · n 498 · Phase 3 · secondary NCT04542057
  • 0.0 vs -0.0 wk 12 · n 477 · Phase 3 · secondary NCT04535986
  • 0.0 vs -0.0 wk 6 · n 498 · Phase 3 · secondary NCT04542057
  • 0.0 vs -0.0 wk 6 · n 477 · Phase 3 · secondary NCT04535986
  • 0.0 vs -0.0 3.0 mg · wk 4 · n 82 · Phase 2 · secondary NCT03443414
  • -0.0 vs -0.0 6.0 mg · wk 4 · n 77 · Phase 2 · secondary NCT03443414
  • 0.2 vs 0.1 6 mg · wk 0.4286 · n 73 · Phase 2 · secondary NCT03673670
  • -0.0 vs -0.0 1.5 mg · wk 4 · n 80 · Phase 2 · secondary NCT03443414
  • 0.2 vs 0.1 1.5 mg · wk 0.4286 · n 74 · Phase 2 · secondary NCT03673670
  • 0.0 vs -0.0 0.75 mg · wk 4 · n 77 · Phase 2 · secondary NCT03443414
  • 0.0 vs -0.1 3 mg · wk 1 · n 22 · Phase 2 · secondary NCT04091360
  • -0.0 vs -0.1 1 mg · wk 1 · n 22 · Phase 2 · secondary NCT04091360
  • -0.1 vs -0.1 0.30 mg · wk 1 · n 22 · Phase 2 · secondary NCT04091360
—Not reported
SGRQ total, change-4.5 vs -4.1−0.5 vs placebowk 24 · n 489NCT04542057
5 other results
  • -6.2 vs -3.9 wk 24 · n 474 · Phase 3 · secondary NCT04535986
  • -4.0 vs -2.9 wk 12 · n 489 · Phase 3 · secondary NCT04542057
  • -5.7 vs -2.7 wk 12 · n 474 · Phase 3 · secondary NCT04535986
  • -3.6 vs -1.9 wk 6 · n 489 · Phase 3 · secondary NCT04542057
  • -6.2 vs -4.0 wk 6 · n 474 · Phase 3 · secondary NCT04535986
—Not reported
TDI focal score1.9 vs 0.8+1.1 vs placebowk 24 · n 471NCT04535986
2 other results
  • 1.6 vs 0.4 wk 12 · n 471 · Phase 3 · secondary NCT04535986
  • 1.3 vs 0.6 wk 6 · n 471 · Phase 3 · secondary NCT04535986
—Not reported

Moderate or severe exacerbations, annualised rate

ensifentrine
—Not posted · NCT05743075
KIT2014
—Not reported

Trough FEV1, change

ensifentrine
-0.0 vs -0.0±0 vs placebowk 24 · n 498NCT04542057
14 other results
  • -0.0 vs -0.0 wk 24 · n 477 · Phase 3 · secondary NCT04535986
  • 0.0 vs -0.0 wk 12 · n 498 · Phase 3 · secondary NCT04542057
  • 0.0 vs -0.0 wk 12 · n 477 · Phase 3 · secondary NCT04535986
  • 0.0 vs -0.0 wk 6 · n 498 · Phase 3 · secondary NCT04542057
  • 0.0 vs -0.0 wk 6 · n 477 · Phase 3 · secondary NCT04535986
  • 0.0 vs -0.0 3.0 mg · wk 4 · n 82 · Phase 2 · secondary NCT03443414
  • -0.0 vs -0.0 6.0 mg · wk 4 · n 77 · Phase 2 · secondary NCT03443414
  • 0.2 vs 0.1 6 mg · wk 0.4286 · n 73 · Phase 2 · secondary NCT03673670
  • -0.0 vs -0.0 1.5 mg · wk 4 · n 80 · Phase 2 · secondary NCT03443414
  • 0.2 vs 0.1 1.5 mg · wk 0.4286 · n 74 · Phase 2 · secondary NCT03673670
  • 0.0 vs -0.0 0.75 mg · wk 4 · n 77 · Phase 2 · secondary NCT03443414
  • 0.0 vs -0.1 3 mg · wk 1 · n 22 · Phase 2 · secondary NCT04091360
  • -0.0 vs -0.1 1 mg · wk 1 · n 22 · Phase 2 · secondary NCT04091360
  • -0.1 vs -0.1 0.30 mg · wk 1 · n 22 · Phase 2 · secondary NCT04091360
KIT2014
—Not reported

SGRQ total, change

ensifentrine
-4.5 vs -4.1−0.5 vs placebowk 24 · n 489NCT04542057
5 other results
  • -6.2 vs -3.9 wk 24 · n 474 · Phase 3 · secondary NCT04535986
  • -4.0 vs -2.9 wk 12 · n 489 · Phase 3 · secondary NCT04542057
  • -5.7 vs -2.7 wk 12 · n 474 · Phase 3 · secondary NCT04535986
  • -3.6 vs -1.9 wk 6 · n 489 · Phase 3 · secondary NCT04542057
  • -6.2 vs -4.0 wk 6 · n 474 · Phase 3 · secondary NCT04535986
KIT2014
—Not reported

TDI focal score

ensifentrine
1.9 vs 0.8+1.1 vs placebowk 24 · n 471NCT04535986
2 other results
  • 1.6 vs 0.4 wk 12 · n 471 · Phase 3 · secondary NCT04535986
  • 1.3 vs 0.6 wk 6 · n 471 · Phase 3 · secondary NCT04535986
KIT2014
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

KIT2014: no structured comparison results are available for Chronic Obstructive Pulmonary Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. ensifentrine: 4 of 4 rows · KIT2014: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricensifentrine
Dropout rate
21.2%a
NCT04542057 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
show 29 more results
16.5%Ensifentrine
NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
—From Week 24 to Week 48: Ensifentr
NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
—Up to Week 24: Ensifentrine
NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
10%3 mg BID
NCT06460493 · Phase 3 · registry result, not featured evidence
0%3 mg
NCT04091360 · Phase 2 · registry result, not featured evidence
—3 mg
NCT04091360 · Phase 2 · registry result, not featured evidence
0%6 mg
NCT04091360 · Phase 2 · registry result, not featured evidence
0%1 mg
NCT04091360 · Phase 2 · registry result, not featured evidence
—1 mg
NCT04091360 · Phase 2 · registry result, not featured evidence
0%0.30 mg
NCT04091360 · Phase 2 · registry result, not featured evidence
—0.30 mg
NCT04091360 · Phase 2 · registry result, not featured evidence
0%0.10 mg
NCT04091360 · Phase 2 · registry result, not featured evidence
—3 mg
NCT04027439 · Phase 2 · registry result, not featured evidence
—3 mg
NCT04027439 · Phase 2 · registry result, not featured evidence
—6 mg
NCT04027439 · Phase 2 · registry result, not featured evidence
—1.5 mg
NCT04027439 · Phase 2 · registry result, not featured evidence
—1.5 mg
NCT04027439 · Phase 2 · registry result, not featured evidence
—0.50 mg
NCT04027439 · Phase 2 · registry result, not featured evidence
—0.50 mg
NCT04027439 · Phase 2 · registry result, not featured evidence
—0.15 mg
NCT04027439 · Phase 2 · registry result, not featured evidence
—0.15 mg
NCT04027439 · Phase 2 · registry result, not featured evidence
—6 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
—1.5 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
7.3%3.0 mg
NCT03443414 · Phase 2 · registry result, not featured evidence
6.3%6.0 mg
NCT03443414 · Phase 2 · registry result, not featured evidence
3.7%1.5 mg
NCT03443414 · Phase 2 · registry result, not featured evidence
13.4%0.75 mg
NCT03443414 · Phase 2 · registry result, not featured evidence
—Higher Dose Nebulised Treatment
NCT03028142 · Phase 2 · registry result, not featured evidence
—Lower Dose Nebulised Treatment
NCT03028142 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
4.2%a
NCT04542057 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
show 29 more results
2.1%Ensifentrine
NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
—From Week 24 to Week 48: Ensifentr
NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
—Up to Week 24: Ensifentrine
NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
—3 mg BID
NCT06460493 · Phase 3 · registry result, not featured evidence
—3 mg
NCT04091360 · Phase 2 · registry result, not featured evidence
—3 mg
NCT04091360 · Phase 2 · registry result, not featured evidence
—6 mg
NCT04091360 · Phase 2 · registry result, not featured evidence
—1 mg
NCT04091360 · Phase 2 · registry result, not featured evidence
—1 mg
NCT04091360 · Phase 2 · registry result, not featured evidence
—0.30 mg
NCT04091360 · Phase 2 · registry result, not featured evidence
—0.30 mg
NCT04091360 · Phase 2 · registry result, not featured evidence
—0.10 mg
NCT04091360 · Phase 2 · registry result, not featured evidence
—3 mg
NCT04027439 · Phase 2 · registry result, not featured evidence
—3 mg
NCT04027439 · Phase 2 · registry result, not featured evidence
—6 mg
NCT04027439 · Phase 2 · registry result, not featured evidence
—1.5 mg
NCT04027439 · Phase 2 · registry result, not featured evidence
—1.5 mg
NCT04027439 · Phase 2 · registry result, not featured evidence
—0.50 mg
NCT04027439 · Phase 2 · registry result, not featured evidence
—0.50 mg
NCT04027439 · Phase 2 · registry result, not featured evidence
—0.15 mg
NCT04027439 · Phase 2 · registry result, not featured evidence
—0.15 mg
NCT04027439 · Phase 2 · registry result, not featured evidence
—6 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
—1.5 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
4.9%3.0 mg
NCT03443414 · Phase 2 · registry result, not featured evidence
2.5%6.0 mg
NCT03443414 · Phase 2 · registry result, not featured evidence
0%1.5 mg
NCT03443414 · Phase 2 · registry result, not featured evidence
7.3%0.75 mg
NCT03443414 · Phase 2 · registry result, not featured evidence
—Higher Dose Nebulised Treatment
NCT03028142 · Phase 2 · registry result, not featured evidence
—Lower Dose Nebulised Treatment
NCT03028142 · Phase 2 · registry result, not featured evidence
Serious AEs
5.6%a
NCT04542057 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
show 29 more results
—Ensifentrine
NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
4.8%From Week 24 to Week 48: Ensifentr
NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
6.7%Up to Week 24: Ensifentrine
NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
0%3 mg BID
NCT06460493 · Phase 3 · registry result, not featured evidence
0%3 mg
NCT04091360 · Phase 2 · registry result, not featured evidence
0%3 mg
NCT04091360 · Phase 2 · registry result, not featured evidence
0%6 mg
NCT04091360 · Phase 2 · registry result, not featured evidence
0%1 mg
NCT04091360 · Phase 2 · registry result, not featured evidence
0%1 mg
NCT04091360 · Phase 2 · registry result, not featured evidence
0%0.30 mg
NCT04091360 · Phase 2 · registry result, not featured evidence
0%0.30 mg
NCT04091360 · Phase 2 · registry result, not featured evidence
0%0.10 mg
NCT04091360 · Phase 2 · registry result, not featured evidence
0%3 mg
NCT04027439 · Phase 2 · registry result, not featured evidence
0%3 mg
NCT04027439 · Phase 2 · registry result, not featured evidence
0%6 mg
NCT04027439 · Phase 2 · registry result, not featured evidence
0%1.5 mg
NCT04027439 · Phase 2 · registry result, not featured evidence
0%1.5 mg
NCT04027439 · Phase 2 · registry result, not featured evidence
0%0.50 mg
NCT04027439 · Phase 2 · registry result, not featured evidence
0%0.50 mg
NCT04027439 · Phase 2 · registry result, not featured evidence
0%0.15 mg
NCT04027439 · Phase 2 · registry result, not featured evidence
0%0.15 mg
NCT04027439 · Phase 2 · registry result, not featured evidence
1.4%6 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
0%1.5 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
1.2%3.0 mg
NCT03443414 · Phase 2 · registry result, not featured evidence
1.3%6.0 mg
NCT03443414 · Phase 2 · registry result, not featured evidence
2.5%1.5 mg
NCT03443414 · Phase 2 · registry result, not featured evidence
2.5%0.75 mg
NCT03443414 · Phase 2 · registry result, not featured evidence
0%Higher Dose Nebulised Treatment
NCT03028142 · Phase 2 · registry result, not featured evidence
3.4%Lower Dose Nebulised Treatment
NCT03028142 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
a
covid-19 3.2% (placebo 3.4%)
headache 2% (placebo 2.4%)
nasopharyngitis 1.8% (placebo 1%)
NCT04542057 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
show 27 more results
nasopharyngitis 2.6% (placebo 0%)
headache 1.8% (placebo 2.9%)
upper respiratory tract infection 1.8% (placebo 0%)
NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
covid-19 3.4% (placebo 2.9%)
headache 3.4% (placebo 2.9%)
nasopharyngitis 2.7% (placebo 0%)
NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
3 mg
dermatitis contact 14.3% (placebo 0%)
headache 14.3% (placebo 0%)
catheter site bruise 0% (placebo 0%)
NCT04091360 · Phase 2 · registry result, not featured evidence
3 mg
catheter site bruise 4.3% (placebo 0%)
haemoptysis 4.3% (placebo 0%)
kidney infection 4.3% (placebo 0%)
NCT04091360 · Phase 2 · registry result, not featured evidence
6 mg
headache 28.6% (placebo 0%)
contusion 14.3% (placebo 0%)
nasopharyngitis 14.3% (placebo 0%)
NCT04091360 · Phase 2 · registry result, not featured evidence
1 mg
headache 16.7% (placebo 0%)
catheter site bruise 0% (placebo 0%)
contusion 0% (placebo 0%)
NCT04091360 · Phase 2 · registry result, not featured evidence
1 mg
dental caries 4.3% (placebo 0%)
dysmenorrhoea 4.3% (placebo 0%)
headache 4.3% (placebo 0%)
NCT04091360 · Phase 2 · registry result, not featured evidence
0.30 mg
nasopharyngitis 14.3% (placebo 0%)
catheter site bruise 0% (placebo 0%)
contusion 0% (placebo 0%)
NCT04091360 · Phase 2 · registry result, not featured evidence
0.30 mg
dizziness postural 4.2% (placebo 0%)
dyspnoea 4.2% (placebo 4%)
headache 4.2% (placebo 0%)
NCT04091360 · Phase 2 · registry result, not featured evidence
0.10 mg
copd 16.7% (placebo 4%)
dry throat 16.7% (placebo 0%)
syncope 16.7% (placebo 0%)
NCT04091360 · Phase 2 · registry result, not featured evidence
3 mg
atrioventricular block first degree 0% (placebo 0%)
blood creatine phosphokinase increased 0% (placebo 0%)
blood thyroid stimulating hormone increased 0% (placebo 0%)
NCT04027439 · Phase 2 · registry result, not featured evidence
3 mg
blood creatine phosphokinase increased 3% (placebo 0%)
blood thyroid stimulating hormone increased 3% (placebo 0%)
hypertension 3% (placebo 0%)
NCT04027439 · Phase 2 · registry result, not featured evidence
6 mg
atrioventricular block first degree 0% (placebo 0%)
blood creatine phosphokinase increased 0% (placebo 0%)
blood thyroid stimulating hormone increased 0% (placebo 0%)
NCT04027439 · Phase 2 · registry result, not featured evidence
1.5 mg
atrioventricular block first degree 14.3% (placebo 0%)
blood creatine phosphokinase increased 0% (placebo 0%)
blood thyroid stimulating hormone increased 0% (placebo 0%)
NCT04027439 · Phase 2 · registry result, not featured evidence
1.5 mg
blood thyroid stimulating hormone increased 6.3% (placebo 0%)
hypertension 6.3% (placebo 0%)
atrioventricular block first degree 0% (placebo 0%)
NCT04027439 · Phase 2 · registry result, not featured evidence
0.50 mg
atrioventricular block first degree 0% (placebo 0%)
blood creatine phosphokinase increased 0% (placebo 0%)
blood thyroid stimulating hormone increased 0% (placebo 0%)
NCT04027439 · Phase 2 · registry result, not featured evidence
0.50 mg
hypertension 6.1% (placebo 0%)
urinary tract infection 6.1% (placebo 0%)
blood creatine phosphokinase increased 3% (placebo 0%)
NCT04027439 · Phase 2 · registry result, not featured evidence
0.15 mg
atrioventricular block first degree 0% (placebo 0%)
blood creatine phosphokinase increased 0% (placebo 0%)
blood thyroid stimulating hormone increased 0% (placebo 0%)
NCT04027439 · Phase 2 · registry result, not featured evidence
0.15 mg
ear infection 2.9% (placebo 0%)
hypertension 2.9% (placebo 0%)
urinary tract infection 2.9% (placebo 0%)
NCT04027439 · Phase 2 · registry result, not featured evidence
6 mg
headache 6.8% (placebo 1.3%)
ventricular extrasystoles 4.1% (placebo 0%)
chronic obstructive pulmonary disease 2.7% (placebo 1.3%)
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
1.5 mg
headache 6.7% (placebo 1.3%)
ventricular extrasystoles 2.7% (placebo 0%)
accelerated idioventricular rhythm 1.3% (placebo 0%)
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
3.0 mg
headache 8.5% (placebo 3.8%)
cough 7.3% (placebo 1.3%)
hypertension 4.9% (placebo 1.3%)
NCT03443414 · Phase 2 · registry result, not featured evidence
6.0 mg
nasopharyngitis 6.3% (placebo 8.9%)
headache 5% (placebo 3.8%)
chronic obstructive pulmonary disease 3.8% (placebo 7.6%)
NCT03443414 · Phase 2 · registry result, not featured evidence
1.5 mg
chronic obstructive pulmonary disease 6.2% (placebo 7.6%)
cough 4.9% (placebo 1.3%)
headache 4.9% (placebo 3.8%)
NCT03443414 · Phase 2 · registry result, not featured evidence
0.75 mg
chronic obstructive pulmonary disease 4.9% (placebo 7.6%)
cough 4.9% (placebo 1.3%)
headache 4.9% (placebo 3.8%)
NCT03443414 · Phase 2 · registry result, not featured evidence
headache 18.5% (placebo 10.7%)
arthralgia 3.7% (placebo 0%)
catheter site bruise 3.7% (placebo 0%)
NCT03028142 · Phase 2 · registry result, not featured evidence
medical device site reaction 13.8% (placebo 14.3%)
headache 6.9% (placebo 10.7%)
chest discomfort 3.4% (placebo 7.1%)
NCT03028142 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 26 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

ensifentrine

FEV1 AUC0-12h 0.103 vs 0.008 placebo L @ 0.14wk3.0 mg
absolute change · L
NCT03443414 · Phase 2 · registry result, not featured evidence
show 17 more results
0.085 vs -0.033 placebo L @ 4wk3.0 mg
NCT03443414 · Phase 2 · registry result, not featured evidence
0.347 vs 0.337 placebo L6 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
0.308 vs 0.303 placebo L6 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
0.095 vs 0.008 placebo L @ 0.14wk6.0 mg
NCT03443414 · Phase 2 · registry result, not featured evidence
0.031 vs -0.033 placebo L @ 4wk6.0 mg
NCT03443414 · Phase 2 · registry result, not featured evidence
0.39 vs 0.337 placebo L1.5 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
0.333 vs 0.303 placebo L1.5 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
0.077 vs 0.008 placebo L @ 0.14wk1.5 mg
NCT03443414 · Phase 2 · registry result, not featured evidence
0.052 vs -0.033 placebo L @ 4wk1.5 mg
NCT03443414 · Phase 2 · registry result, not featured evidence
0.088 vs 0.008 placebo L @ 0.14wk0.75 mg
NCT03443414 · Phase 2 · registry result, not featured evidence
0.039 vs -0.033 placebo L @ 4wk0.75 mg
NCT03443414 · Phase 2 · registry result, not featured evidence
0.048 vs -0.0462 placebo L @ 12wk
NCT04542057 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
0.0611 vs -0.0256 placebo L @ 12wk
NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
3.804 vs 3.197 placebo L @ 0.43wk
NCT03028142 · Phase 2 · registry result, not featured evidence
3.967 vs 3.197 placebo L @ 0.43wk
NCT03028142 · Phase 2 · registry result, not featured evidence
3.058 vs 2.51 placebo L @ 0.14wk
NCT03028142 · Phase 2 · registry result, not featured evidence
3.094 vs 2.51 placebo L @ 0.14wk
NCT03028142 · Phase 2 · registry result, not featured evidence
FEV1 Peak 0.31 vs -0.016 placebo L @ 1wk3 mg
absolute change · L
NCT04091360 · Phase 2 · registry result, not featured evidence
show 32 more results
0.332 vs 0.086 placebo L @ 0.14wk3 mg
NCT04091360 · Phase 2 · registry result, not featured evidence
0.337 vs 0.079 placebo L @ 0.14wk3 mg
NCT04091360 · Phase 2 · registry result, not featured evidence
0.257 vs 0.057 placebo L @ 4wk3.0 mg
NCT03443414 · Phase 2 · registry result, not featured evidence
0.477 vs 0.086 placebo L @ 0.14wk6 mg
NCT04091360 · Phase 2 · registry result, not featured evidence
0.506 vs 0.519 placebo L6 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
0.467 vs 0.445 placebo L6 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
0.405 vs 0.324 placebo L6 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
0.196 vs 0.057 placebo L @ 4wk6.0 mg
NCT03443414 · Phase 2 · registry result, not featured evidence
0.565 vs 0.519 placebo L1.5 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
0.49 vs 0.445 placebo L1.5 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
0.453 vs 0.324 placebo L1.5 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
0.209 vs 0.057 placebo L @ 4wk1.5 mg
NCT03443414 · Phase 2 · registry result, not featured evidence
0.261 vs -0.016 placebo L @ 1wk1 mg
NCT04091360 · Phase 2 · registry result, not featured evidence
0.255 vs 0.086 placebo L @ 0.14wk1 mg
NCT04091360 · Phase 2 · registry result, not featured evidence
0.311 vs 0.079 placebo L @ 0.14wk1 mg
NCT04091360 · Phase 2 · registry result, not featured evidence
0.203 vs 0.057 placebo L @ 4wk0.75 mg
NCT03443414 · Phase 2 · registry result, not featured evidence
0.189 vs -0.016 placebo L @ 1wk0.30 mg
NCT04091360 · Phase 2 · registry result, not featured evidence
0.264 vs 0.086 placebo L @ 0.14wk0.30 mg
NCT04091360 · Phase 2 · registry result, not featured evidence
0.253 vs 0.079 placebo L @ 0.14wk0.30 mg
NCT04091360 · Phase 2 · registry result, not featured evidence
0.133 vs 0.086 placebo L @ 0.14wk0.10 mg
NCT04091360 · Phase 2 · registry result, not featured evidence
0.2369 vs 0.0801 placebo L @ 0.14wk
NCT04542057 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
0.2158 vs 0.0636 placebo L @ 6wk
NCT04542057 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
0.1945 vs 0.0482 placebo L @ 12wk
NCT04542057 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
0.1957 vs 0.0434 placebo L @ 24wk
NCT04542057 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
0.2274 vs 0.0755 placebo L @ 0.14wk
NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
0.2038 vs 0.0677 placebo L @ 6wk
NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
0.2042 vs 0.057 placebo L @ 12wk
NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
0.1623 vs 0.0462 placebo L @ 24wk
NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
0.477 vs 0.373 placebo L @ 0.43wk
NCT03028142 · Phase 2 · registry result, not featured evidence
0.5 vs 0.373 placebo L @ 0.43wk
NCT03028142 · Phase 2 · registry result, not featured evidence
0.383 vs 0.337 placebo L @ 0.14wk
NCT03028142 · Phase 2 · registry result, not featured evidence
0.432 vs 0.337 placebo L @ 0.14wk
NCT03028142 · Phase 2 · registry result, not featured evidence
E-RS Total -1.938 vs -0.614 placebo score @ 6wk
absolute change · score
NCT04542057 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
show 5 more results
-2.051 vs -1.161 placebo score @ 12wk
NCT04542057 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
-2.146 vs -1.529 placebo score @ 24wk
NCT04542057 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
-1.944 vs -1.157 placebo score @ 6wk
NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
-2.498 vs -1.127 placebo score @ 12wk
NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
-2.249 vs -1.298 placebo score @ 24wk
NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
SGRQ Total -3.602 vs -1.89 placebo score @ 6wk
absolute change · score
NCT04542057 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
show 5 more results
-4.019 vs -2.942 placebo score @ 12wk
NCT04542057 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
-4.532 vs -4.054 placebo score @ 24wk
NCT04542057 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
-6.184 vs -3.965 placebo score @ 6wk
NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
-5.665 vs -2.652 placebo score @ 12wk
NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
-6.167 vs -3.868 placebo score @ 24wk
NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
FEV1 Trough 0.013 vs -0.097 placebo L @ 1wk3 mg
absolute change · L
NCT04091360 · Phase 2 · registry result, not featured evidence
show 14 more results
0.04 vs -0.028 placebo L @ 4wk3.0 mg
NCT03443414 · Phase 2 · registry result, not featured evidence
0.178 vs 0.15 placebo L @ 0.4286wk6 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
-0.026 vs -0.028 placebo L @ 4wk6.0 mg
NCT03443414 · Phase 2 · registry result, not featured evidence
0.186 vs 0.15 placebo L @ 0.4286wk1.5 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
-0.019 vs -0.028 placebo L @ 4wk1.5 mg
NCT03443414 · Phase 2 · registry result, not featured evidence
-0.017 vs -0.097 placebo L @ 1wk1 mg
NCT04091360 · Phase 2 · registry result, not featured evidence
0.007 vs -0.028 placebo L @ 4wk0.75 mg
NCT03443414 · Phase 2 · registry result, not featured evidence
-0.051 vs -0.097 placebo L @ 1wk0.30 mg
NCT04091360 · Phase 2 · registry result, not featured evidence
0.0177 vs -0.0261 placebo L @ 6wk
NCT04542057 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
0.0057 vs -0.0435 placebo L @ 12wk
NCT04542057 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
-0.0066 vs -0.0318 placebo L @ 24wk
NCT04542057 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
0.0112 vs -0.0259 placebo L @ 6wk
NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
0.0076 vs -0.0272 placebo L @ 12wk
NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
-0.0236 vs -0.0369 placebo L @ 24wk
NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
FEV1 AUC0-4h 0.39 vs 0.377 placebo L6 mg
absolute change · L
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
show 9 more results
0.429 vs 0.377 placebo L1.5 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
0.1556 vs 0.0063 placebo L @ 0.14wk
NCT04542057 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
0.1357 vs -0.0082 placebo L @ 6wk
NCT04542057 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
0.1148 vs -0.0209 placebo L @ 12wk
NCT04542057 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
0.1148 vs -0.0248 placebo L @ 24wk
NCT04542057 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
0.1495 vs 0.0099 placebo L @ 0.14wk
NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
0.1259 vs -0.0044 placebo L @ 6wk
NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
0.1243 vs -0.0149 placebo L @ 12wk
NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
0.0875 vs -0.0139 placebo L @ 24wk
NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
SGRQ 44% (n=489) vs 39.5% (n=286) placebo @ 6wk
responder rate · % of participants
NCT04542057 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
show 5 more results
45.2% (n=489) vs 43% (n=286) placebo @ 12wk
NCT04542057 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
45.4% (n=489) vs 50.3% (n=286) placebo @ 24wk
NCT04542057 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
50.8% (n=474) vs 40.6% (n=281) placebo @ 6wk
NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
52.5% (n=474) vs 37% (n=281) placebo @ 12wk
NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
58.2% (n=474) vs 45.9% (n=281) placebo @ 24wk
NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
TDI Total 1.6 vs 0.9 placebo score @ 6wk
absolute value · score
NCT04542057 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
show 2 more results
1.8 vs 1.2 placebo score @ 12wk
NCT04542057 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
2.2 vs 1.3 placebo score @ 24wk
NCT04542057 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
FEV1 Evening Trough -0.0246 vs -0.0783 placebo L @ 12wk
absolute change · L
NCT04542057 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
show 1 more result
-0.0117 vs -0.0697 placebo L @ 12wk
NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
Rescue Puffs -0.442 vs -0.306 placebo per week @ 6wk
absolute change · per week
NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
show 2 more results
-0.469 vs -0.182 placebo per week @ 12wk
NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
-0.506 vs -0.052 placebo per week @ 24wk
NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
TDI Focal 1.3 vs 0.6 placebo score @ 6wk
absolute change · score
NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
show 2 more results
1.6 vs 0.4 placebo score @ 12wk
NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
1.9 vs 0.8 placebo score @ 24wk
NCT04535986 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3
CAT 66.7% (n=18) @ 12wk3 mg BID
responder rate · % of participants
No placebo or comparator arm
NCT06460493 · Phase 3 · registry result, not featured evidence · converted to % from 12 Participants as posted
show 1 more result
44.4% (n=18) @ 6wk*3 mg BID
NCT06460493 · Phase 3 · registry result, not featured evidence · converted to % from 8 Participants as posted

+ 15 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ensifentrine's landscape · KIT2014's landscape